These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 24770557)

  • 1. Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients.
    Akers KS; Niece KL; Chung KK; Cannon JW; Cota JM; Murray CK
    J Trauma Acute Care Surg; 2014 Sep; 77(3 Suppl 2):S163-70. PubMed ID: 24770557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ; Shankar V; Schlichting C; Kuti JL
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
    Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
    Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
    Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
    Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
    Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.
    Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA;
    J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
    Bao H; Lv Y; Wang D; Xue J; Yan Z
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying augmented renal clearance in trauma patients: Validation of the Augmented Renal Clearance in Trauma Intensive Care scoring system.
    Barletta JF; Mangram AJ; Byrne M; Sucher JF; Hollingworth AK; Ali-Osman FR; Shirah GR; Haley M; Dzandu JK
    J Trauma Acute Care Surg; 2017 Apr; 82(4):665-671. PubMed ID: 28129261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M; Martín-Loeches I; Llauradó-Serra M; Fernández J; Vaquer S; Rodríguez A; Pontes C; Calvo G; Torres A; Soy D
    J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.